



LUMOS
DIAGNOSTICS

ASX ANNOUNCEMENT

Lumos Announces Expanded Scope of Work under Hologic fFN Development Agreement

Key Highlights

- Lumos and Hologic agree to expand the scope of work for the new fetal fibronectin (fFN) test
- Expanded work to be incorporated within Phase 3 of the Development Agreement, delivering new hardware features to Hologic with an additional fee to Lumos of between US\$0.6 – US\$0.8 million
- Phase 2 expected to complete around April 2025

MELBOURNE, Australia (3 March 2025) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to announce an agreement to expand the scope of work under the Development Agreement covering the new fetal fibronectin (“fFN”) test for leading women’s health company, Hologic, Inc. (NASDAQ: HOLX) (ASX: 11 January 2024).

The expanded scope of work relates to Phase 3 of the Development Agreement, which focuses on delivery of the system prototype. This phase will now include incorporating additional hardware features into the proprietary reader technology. The expanded scope of work is estimated to generate additional fee revenue for Lumos of between US\$0.6 - US\$0.8 million, to be invoiced as the work is completed over the coming months.

As previously announced, the body of work under the Development Agreement is being conducted across three phases, providing total milestone payments of up to US\$4.7 million, structured as follows:

- Phase 1 - Product Definition and Planning: define the parameters for the product and establish a project plan - US\$0.4 million - completed as announced on 6 May 2024. Payment has been received for this phase;

- Phase 2 - Assay Feasibility: conduct work to demonstrate the assay can detect the biomarker - US\$0.6 million – work on the first milestone of this phase has been completed, comprising US\$0.3 million payment, as announced on 20 September 2024, and payment has been received. Work on the second and final milestone for this phase, worth \$0.3 million is ongoing and expected to complete by around April 2025; and
- Phase 3 - System Prototype Delivery: deliver a working prototype of the system - US\$3.7 million. Work on this phase has commenced and is expected to complete by around December 2025.

The value of this Phase 3, including the expanded scope of works is now between US\$4.3 – US\$4.5 million, bringing the total value of the Development Agreement to around US\$5.3 - US\$5.5 million.

As announced in the Q2 FY25 quarterly report (ASX: 31 January 2025), the total project timeline is now expected to around 24 months, running from January 2024 to December 2025, including the additional hardware scope of works announced here.

Commenting on the announcement, Doug Ward, Managing Director of Lumos Diagnostics, said: *"We are extremely pleased with the progress of the Hologic fFN project. Phase 2 of the project is progressing well and is expected to complete around April 2025, triggering the second of the Phase 2 milestone payments, worth US\$0.3 million. In collaboration with the Hologic team, Phase 3 will now deliver a more feature rich product."*

Lumos will continue to keep the market updated as we progress through the remaining milestones under the Development Agreement.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 (0) 423 139 163

Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598